Profile data is unavailable for this security.
About the company
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
- Revenue in USD (TTM)20.71m
- Net income in USD-72.50m
- Incorporated2008
- Employees107.00
- LocationCarisma Therapeutics Inc245 1st St Ste 1800CAMBRIDGE 02142-1292United StatesUSA
- Phone+1 (617) 444-8550
- Fax+1 (617) 858-0911
- Websitehttps://sesenbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tempest Therapeutics Inc | 0.00 | -31.75m | 35.54m | 17.00 | -- | 2.04 | -- | -- | -1.64 | -1.64 | 0.00 | 0.6921 | 0.00 | -- | -- | 0.00 | -87.09 | -57.10 | -127.72 | -71.20 | -- | -- | -- | -- | -- | -368.16 | 0.3861 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Protara Therapeutics Inc | 0.00 | -40.69m | 36.31m | 26.00 | -- | 0.3944 | -- | -- | -3.19 | -3.19 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -41.35 | -37.02 | -43.70 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
Surrozen Inc | 0.00 | -53.45m | 36.35m | 42.00 | -- | 6.00 | -- | -- | -21.74 | -21.74 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -98.01 | -- | -110.62 | -- | -- | -- | -- | -- | -- | -2.05 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 36.86m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
Passage Bio Inc | 0.00 | -76.57m | 37.12m | 58.00 | -- | 0.4099 | -- | -- | -1.36 | -1.36 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -47.99 | -48.56 | -53.39 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
Singular Genomics Systems Inc | 2.72m | -91.89m | 37.76m | 255.00 | -- | 0.2738 | -- | 13.87 | -37.37 | -37.37 | 1.11 | 55.27 | 0.0108 | 0.2867 | 11.53 | 10,674.51 | -36.46 | -- | -38.85 | -- | -41.11 | -- | -3,375.72 | -- | 8.04 | -- | 0.0696 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
NextCure Inc | 0.00 | -61.28m | 37.77m | 82.00 | -- | 0.442 | -- | -- | -2.20 | -2.20 | 0.00 | 3.05 | 0.00 | -- | -- | 0.00 | -47.88 | -22.59 | -51.64 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
Carisma Therapeutics Inc | 20.71m | -72.50m | 39.17m | 107.00 | -- | 108.80 | -- | 1.89 | -1.78 | -1.78 | 0.5075 | 0.0087 | 0.2153 | -- | -- | 193,551.40 | -75.38 | -30.87 | -91.33 | -34.47 | -- | -- | -350.08 | -255.66 | -- | -- | 0.8322 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
DURECT Corp | 8.41m | -15.80m | 39.42m | 47.00 | -- | 7.83 | -- | 4.69 | -0.5283 | -0.5283 | 0.2842 | 0.1623 | 0.2143 | 0.682 | 7.26 | 145,017.20 | -40.25 | -37.34 | -208.53 | -53.44 | 80.80 | 91.83 | -187.84 | -139.11 | 0.797 | -38.83 | 0.7135 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -35.51m | 40.04m | 15.00 | -- | -- | -- | -- | -1.30 | -1.30 | 0.00 | -0.2026 | 0.00 | -- | -- | 0.00 | -356.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
Lantern Pharma Inc | 0.00 | -17.75m | 40.15m | 21.00 | -- | 1.30 | -- | -- | -1.65 | -1.65 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -40.79 | -28.83 | -44.71 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
Estrella Immunopharma Inc | 0.00 | -6.29m | 40.17m | -- | -- | 9.43 | -- | -- | -0.1687 | -0.1687 | 0.00 | 0.1178 | 0.00 | -- | -- | -- | -168.15 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
OncoCyte Corp | 1.02m | -36.80m | 40.26m | 43.00 | -- | 1.77 | -- | 39.35 | -4.26 | -4.26 | 0.1087 | 1.70 | 0.0126 | -- | 1.14 | 23,790.70 | -44.55 | -35.11 | -49.04 | -39.71 | 8.11 | -- | -3,532.75 | -2,373.36 | -- | -154.75 | 0.0212 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Clene Inc. | 442.00k | -30.46m | 40.34m | 82.00 | -- | -- | -- | 91.26 | -4.74 | -4.74 | 0.0688 | -0.0783 | 0.0082 | 1.89 | 5.49 | 5,390.24 | -56.31 | -39.43 | -81.90 | -47.32 | 81.00 | -- | -6,890.50 | -5,261.20 | 0.993 | -16.96 | 1.02 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
Calcimedica Inc | 0.00 | -12.59m | 42.57m | 14.00 | -- | 3.08 | -- | -- | -1.88 | -1.88 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -60.97 | -63.99 | -75.48 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.60m | 3.84% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.56m | 3.76% |
University of Pennsylvania (Investment)as of 31 Mar 2024 | 1.25m | 3.01% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 525.11k | 1.26% |
Geode Capital Management LLCas of 30 Jun 2024 | 283.41k | 0.68% |
Bridgeway Capital Management LLCas of 31 Mar 2024 | 214.88k | 0.52% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 210.70k | 0.51% |
Renaissance Technologies LLCas of 30 Jun 2024 | 139.36k | 0.34% |
BlackRock Investment Management LLCas of 31 Mar 2024 | 78.39k | 0.19% |
Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 60.95k | 0.15% |